".. What should investors look out for in digital health stocks?
Most importantly the ability to have a regulatory approval or a proven and well-identified pathway towards it. Without regulatory approval these companies will never make a dollar. Existing clinical data (ie robust, completed clinical studies) is a must.
The most attractive component of investing in digital healthcare companies is that their clinical studies cost a fraction of those conducted by traditional biotech or pharma companies and can be completed in months.
It’s a dream for any head of R&D....'